2 new injectable diabetes medicines that have similar adverse reactions and disease reduction rate are on the market. Yay for Novo nordisks' shateholders as of this friday.
"The agency originally refused to approve Tresiba and Ryzodeg 2 years ago, citing concerns about the drugs’ adverse cardiovascular effects. But in April, the FDA began reviewing resubmitted regulatory applications for the treatments, which ultimately led to their approvals today."
- See more at: http://www.pharmacytimes.com/product-news/fda-approves-2-previously-rejected-diabetes-drugs#sthash.n5WEpWnk.dpuf
No comments:
Post a Comment